BioNTech SE (BNTX) Non-Current Debt (2018 - 2025)
BioNTech SE (BNTX) posted Non-Current Debt of $361.0 million for Q4 2025, up 29.13% sequentially from $279.5 million in Q4 2024, and up 29.13% YoY from $279.5 million in Q4 2024.
BioNTech SE (BNTX) Non-Current Debt (2018 - 2025) Analysis & Trends
BioNTech SE has reported Non-Current Debt for 8 years, with the latest figure at $361.0 million in Q4 2025.
- Quarterly Non-Current Debt rose 29.13% year-over-year to $361.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $361.0 million (up 29.13% YoY) and the FY2025 annual result came in at $350.4 million, up 25.33% from the prior year.
- Non-Current Debt rose to $361.0 million in Q4 2025 per BNTX's latest filing, from $279.5 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $361.0 million in Q4 2025 and troughed at $6.2 million in Q4 2022.
- A 5-year average of $178.4 million and a median of $203.3 million in 2021 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt plunged 96.94% in 2022, then soared 570.79% in 2023.
- Over 5 years, Non-Current Debt stood at $203.3 million in 2021, then slumped by 96.94% to $6.2 million in 2022, then jumped by 570.79% to $41.7 million in 2023, then soared by 569.62% to $279.5 million in 2024, then gained by 29.13% to $361.0 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $361.0 million, $279.5 million, and $41.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | 360.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 360.97 Mn |
| Dec 31, 2024 | 50.12 Mn |
| Dec 31, 2023 | 41.75 Mn |
| Dec 31, 2022 | 6.22 Mn |
| Dec 31, 2021 | 203.28 Mn |
| Dec 31, 2020 | 275.42 Mn |
| Dec 31, 2019 | 76.27 Mn |
| Sep 30, 2019 | 75.46 Mn |
| Dec 31, 2018 | 61.88 Mn |